Related Experiment Video
Updated: Jul 14, 2026
07:27
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
Published on: October 21, 2017
11.8K
Copper hepatopathies in Australian dogs.
J Mutton1, S Yeomans2, J White1
1Internal Medicine Department, Small Animal Specialist Hospital, North Ryde, New South Wales, Australia.
Australian Veterinary Journal
|April 29, 2024
Summary
Copper-associated hepatopathy is common in Australian dogs, affecting younger and heavier dogs. Treatment offers a good prognosis, and this study is the first to report it in Australian Cavalier King Charles Spaniels.
Area of Science:
- Veterinary Medicine
- Hepatology
- Canine Health
Background:
- Hepatopathies are common in dogs.
- Evaluating canine liver disease according to WSAVA guidelines is crucial.
- Copper-associated hepatopathy requires specific diagnostic criteria.
Purpose of the Study:
- To evaluate hepatopathies in Australian dogs using WSAVA guidelines.
- To determine the prevalence and survival rates of dogs with copper-associated hepatopathy.
- To identify breed predispositions for copper-associated hepatopathy.
Main Methods:
- Retrospective review of medical records from 2008-2021.
- Histopathological classification of liver disease according to WSAVA guidelines.
- Statistical comparison of clinical and survival data between copper-associated hepatopathy and other chronic inflammatory liver diseases.
Main Results:
- Copper-associated hepatopathy was diagnosed in 13 of 67 dogs.
- Dogs with copper-associated hepatopathy were younger and heavier than those with other liver diseases.
- No significant differences in survival or routine clinical pathology markers were found between groups.
Conclusions:
- Copper-associated hepatopathy is a prevalent condition in Australian dogs.
- Clinical pathology is not a reliable differentiator for copper-associated hepatopathy.
- Prognosis for copper-associated hepatopathy is favorable with treatment.
- First report of copper-associated hepatopathy in Australian Cavalier King Charles Spaniels.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...